A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the pr...
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake...
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline....
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01....
DIALYSIS-TIR Study
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide t...
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated ...
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...
A Study on TLC590 for Managing Postsurgical Pain
This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolera...
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomy...
Regeneron AA Multicenter (Dupilumab)
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affe...
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs
The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dos...
Aβ Dynamics in LLMD
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depressio...
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. Th...
Letrozole in Uterine Leiomyosarcoma
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will recei...
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be...
Top Cities for Sarcoma Soft Tissue Clinical Trials
Sarcoma Soft Tissue clinical trials are recruiting across 69 cities. Here are the cities with the most active studies:
About Sarcoma Soft Tissue
Soft tissue sarcomas are rare cancers that develop in the soft tissues of the body including muscle, fat, blood vessels, and tendons. There are more than 50 subtypes, each with different characteristics. Treatment includes surgery, radiation, and chemotherapy, with newer targeted therapies under investigation.
Clinical trials are advancing new treatments for sarcoma soft tissue. Currently, 18 studies are recruiting a combined 4,336 participants across the United States. Research is being conducted by 17 organizations including Eli Lilly and Company, Immunocore Ltd, PharmaMar and 14 others.
2026 Sarcoma Soft Tissue Research Landscape
As of March 2026, the sarcoma soft tissue clinical trial landscape includes 18 actively recruiting studies across 69 cities in the United States. These studies are collectively seeking 4,336 participants, with an average enrollment target of 241 per study.
Research is being led by 17 different organizations, including Eli Lilly and Company, Immunocore Ltd, PharmaMar, Rutgers, The State University of New Jersey, Merck Sharp & Dohme LLC, and 12 others. The large number of sponsors reflects significant research interest and investment in sarcoma soft tissue treatment advancement.
Geographically, sarcoma soft tissue trials are most concentrated in New York, New York (6 trials); Los Angeles, California (5 trials); Aurora, Colorado (5 trials); Chicago, Illinois (4 trials); Boston, Massachusetts (4 trials) and 7 other cities.
Featured Sarcoma Soft Tissue Studies
Highlighted recruiting studies for sarcoma soft tissue, selected by enrollment size and research scope.
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent pa...
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Frequently Asked Questions About Sarcoma Soft Tissue Clinical Trials
Are there sarcoma soft tissue clinical trials near me?
Yes, there are 18 sarcoma soft tissue clinical trials currently recruiting across 69+ cities in the United States, including New York, New York; Los Angeles, California; Aurora, Colorado. Browse the studies above to find one at a location convenient for you.
How do I join a sarcoma soft tissue clinical trial?
To join a sarcoma soft tissue clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are sarcoma soft tissue clinical trials free?
Yes, participation in sarcoma soft tissue clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of sarcoma soft tissue treatments are being studied?
Current sarcoma soft tissue clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 17 research organizations.
Is it safe to participate in sarcoma soft tissue clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov